$HYFT: Cup & Handle Breakout in Play 🚨‼️
MindWalk Holdings Corp is forming a classic cup and handle pattern, a bullish setup that often signals trend continuation. After an extended consolidation, price has reclaimed key resistance in the $2.50–$2.65 zone, suggesting renewed strength.
Technical highlights:
📈Clear cup and handle formation on the daily chart
📈Breakout above prior resistance with solid follow-through
📈Higher-low structure signaling improving demand
📈Measured move upside targets near $3.60 → $4.40 → $4.90
Adding to the setup, MindWalk announced a share repurchase program on Oct 9, 2025, a shareholder-friendly catalyst that could help tighten supply as price approaches higher levels.
If volume continues to support the move, HYFT may be entering a new bullish leg, with momentum traders watching closely as the pattern develops.
Communicated Disclaimer: https://bit.ly/45yIR8a
Sector Peers: $CRSP $IGMS $ANTX $CABA
📌 $HYFT : Weekly Chart Setting Up for Expansion
MindWalk holdings is pressing into key weekly resistance near $3.25, aligning with the cup level on the weekly timeframe and signaling growing upside potential.
🔍 Weekly structure highlights:
🔹 Price is firmly challenging the $3.25 weekly cup level
🔹 Strong recovery from long term lows with clear higher-low structure
🔹 Momentum accelerating as price moves through the base
🎯 Upside levels in focus as momentum builds:
📈 $3.65
📈 $4.00
📈 $4.40
📈 $4.90
📈 $5.43
📈 $5.90–$6.50 zone
A sustained push through $3.25 on the weekly sets the stage for a broader move higher, with the chart offering clear expansion potential into upper resistance bands.
Positive market reaction to recent breakthroughs reinforces HYFT’s positioning as a potential platform winner in the multi billion dollar influenza vaccine market.
Communicated Disclaimer: https://bit.ly/45yIR8a
Sector Peers: $IGMS $ANTX $CABA $ENTX
$HYFT: Riding the AI Biotech Wave Into Its Next Stage of Growth
With AI fueling a new era of biotech breakthroughs, MindWalk is perfectly positioned, merging deep tech and biology to accelerate discoveries the entire sector has been waiting for.
📞 Conference Call Coming Up
As the call approaches, investors are looking for clarity on HYFT’s accelerating momentum. Key topics expected to be discussed include:
➖ Record Q2 revenue growth and margin expansion
➖ Updates on the GLP-1 + longevity programs and dengue vaccine progress
➖ Strategic direction heading into the mid-January JPM update
💰 Strengthened by September’s Strategic Move
On Sept 15, MindWalk sold its Netherlands operations, unlocking over $14M. That capital is now being directed into HYFT’s core BioNative AI platform and wet lab programs.
Communicated Disclaimer : https://tinyurl.com/58pvrf5j
Sector Peers: $FATE $IGMS $ANTX $CABA
$IGMS | Primer: IGM Biosciences Inc (IGMS US) - Oct 2025
"IGM Biosciences is a clinical-stage biotechnology company centered on a proprietary platform for developing engineered Immunoglobulin M (IgM)..." - αSK (Smartkarma)
Read more: https://www.smartkarma.com/insights/primer-igm-biosciences-inc-igms-us-oct-2025
$IGMS IGM Biosciences (IGMS) stock has been halted in anticipation of a merger with Concentra Biosciences. The tender offer for the acquisition is set to expire, and the merger is expected to close soon. Trading was halted at the end of the after-hours session on August 13, 2025, and will remain halted on August 14, 2025, with the stock being suspended from trading effective August 15, 2025.
$IGMS NASDAQ Equity Corporate Actions Alert # 2025 - 436
Information Regarding the Tender Offer of IGM Biosciences, Inc. (IGMS)
https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-436
The tender offer by Concentra Biosciences to acquire all of the outstanding common stock of IGM Biosciences, Inc. (IGMS) is scheduled to expire one minute after 11:59 p.m. ET on August 13, 2025, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on August 14, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on August 13, 2025. If the merger closes as planned, the stock will remain halted on the day of closing (August 14) and will be suspended effective August 15, 2025.
Tender offer: $1.247 for each IGMS share held plus one non-tradeable contingent value right (CVR).
$IGMS I was yelling short this when it was a high flyer two years ago - the CEO it was clear that this thing was going to a dollar. He’s just lucky to not be sued for incompetence.
$IGMS Really good write-up that perfectly summarizes IGMS's present situation. So if you want to bring your IGMS knowledge up to date or just discover IGMS, this is required reading. https://beyondspx.com/article/igm-biosciences-a-strategic-pivot-culminates-in-acquisition-valuing-cash-and-contingent-upside-igms
$IGMS
1.so we will lose ownership of the shares we have on this stock ?
2. the share holders are obligated to agree with the price or cand they keep the shares of igms till they become shares of the new company?
Cand anyone help me understand!?
$IGMS
Biotech M&A Alert: IGM Biosciences (NASDAQ: $IGMS) is being acquired by Concentra Biosciences in a cash + CVR deal that could unlock even more value for shareholders. Stock is up 18% as the market reacts. Deal expected to close by August!
